IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Holdings Reduced by Edgestream Partners L.P.

Edgestream Partners L.P. lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 87.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,237 shares of the company's stock after selling 8,340 shares during the period. Edgestream Partners L.P.'s holdings in IDEXX Laboratories were worth $625,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in IDXX. International Assets Investment Management LLC lifted its stake in shares of IDEXX Laboratories by 52,746.0% in the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock worth $2,669,890,000 after acquiring an additional 527,460 shares during the period. Clearbridge Investments LLC grew its holdings in IDEXX Laboratories by 696.0% during the second quarter. Clearbridge Investments LLC now owns 352,814 shares of the company's stock worth $171,891,000 after acquiring an additional 308,493 shares during the period. Vontobel Holding Ltd. grew its stake in shares of IDEXX Laboratories by 3,325.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company's stock worth $111,229,000 after purchasing an additional 213,731 shares during the period. American Century Companies Inc. grew its stake in IDEXX Laboratories by 46.0% in the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company's stock valued at $274,179,000 after acquiring an additional 177,226 shares during the last quarter. Finally, 1832 Asset Management L.P. increased its holdings in IDEXX Laboratories by 4,193.1% during the 2nd quarter. 1832 Asset Management L.P. now owns 128,491 shares of the company's stock valued at $62,601,000 after acquiring an additional 125,498 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now owns 905 shares in the company, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.11% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Piper Sandler reissued a "neutral" rating and set a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a research report on Thursday, October 10th. Leerink Partners initiated coverage on IDEXX Laboratories in a research report on Monday. They set an "outperform" rating and a $500.00 price objective for the company. JPMorgan Chase & Co. reduced their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. Finally, StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, November 28th. Two analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $546.56.

IDEXX Laboratories Stock Up 1.4 %

Shares of NASDAQ:IDXX traded up $6.07 during mid-day trading on Friday, hitting $433.56. 280,367 shares of the company traded hands, compared to its average volume of 509,954. The firm has a market cap of $35.50 billion, a P/E ratio of 41.22, a PEG ratio of 3.95 and a beta of 1.37. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39. The firm's 50 day simple moving average is $445.99 and its 200 day simple moving average is $475.13. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. During the same period in the previous year, the company earned $2.53 earnings per share. The company's revenue for the quarter was up 6.6% compared to the same quarter last year. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.